Every AXLRx ATTR Amyloidosis report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
Tafamidis's ATTR-CM monopoly meets acoramidis — while the orphan-drug exclusion keeps the stabilizer class out of IRA price negotiation.
Tafamidis is shielded from IRA negotiation by the orphan-drug exclusion — ICER judged its ~$268K price ~85–95% too high, and acoramidis plus pending generics are the real net-price levers.
The ATTR-CM vs ATTR-PN split, the wild-type/hereditary divide, and why Tc-PYP scintigraphy, not biopsy, is now the diagnostic gate for a largely undiagnosed population.
Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser.
Tafamidis is SFDA-registered and tender-priced 80-90% below US list, but ATTR-CM in the GCC is a pre-commercial opportunity gated by Tc-PYP scintigraphy availability at fewer than 8 centres, not by drug access.
No ATTR-CM treatment is SFDA-registered in GCC — the binding constraint is diagnosis, not competition: without Tc-PYP expansion beyond four centres, a first-mover drug has almost no diagnosed patients to treat.
Why GCC tafamidis costs roughly a tenth of its US price yet uptake is limited not by affordability but by Tc-PYP scintigraphy access at fewer than 8 GCC centres.
NICE-commissioned tafamidis access (TA696, updated by TA984), a 30-centre Tc-PYP diagnostic pathway, and vutrisiran's TA868 PAS-backed approval reshaping UK ATTR identification and treatment.
500,000+ US patients aged 70+ with HFpEF carry undiagnosed ATTRwt-CM, against only 70,000-100,000 diagnosed and treated. Two further sub-populations, Val122Ile carriers and ATTR-PN, remain even less visible.
True UK ATTRwt-CM prevalence runs 20,000-40,000, and 15,000-36,000 of those patients remain undiagnosed. Only 3,000-4,000 are on NHS-commissioned tafamidis today, adding 1,500-2,000 a year.
Two GCC ATTR-CM burden estimates, 15,000-25,000 and a narrower 2,000-5,000 ATTRwt-CM cohort, both convert to fewer than 1,000 confirmed diagnoses. This model reconciles the gap and traces it to scintigraphy access.
GCC ATTR-CM burden runs 15,000-25,000 by broad HFpEF-adjacent estimate, or 2,000-5,000 by the narrower near-term-addressable ATTRwt-CM cohort, and fewer than 8 centres with scintigraphy capacity explain why so few of either total converts to a confirmed diagnosis.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it.
Why any new ATTR-CM entrant is judged against tafamidis on NICE's TA984 QALY bar, now joined by acoramidis's TA1121 recommendation, the diagnosis pipeline still leaving 15,000-36,000 UK patients undiagnosed, and why the National Amyloidosis Centre is the single investment that decides the outcome.
Binding constraint: capture newly diagnosed ATTR-CM volume and survive ICER's steepest value gap in the rare-disease basket.
NICE recommends both ATTR-CM stabilisers, tafamidis (TA984) and acoramidis (TA1121), and directs clinicians to the cheaper one. Acoramidis cleared on indirect comparison alone. A third entrant must beat an invisible, PAS-discounted floor, with no published price target.
Tafamidis prices 12-17x above ICER's fair-value benchmark, yet the orphan-drug exclusion keeps it out of IRA negotiation. Acoramidis and pending generics, not Medicare, now set net price.
NICE's TA1121 cost-minimisation rule directs clinicians to whichever ATTR-CM stabiliser costs less. That rule, not the QALY threshold alone, now sets a new entrant's UK price ceiling.
GCC tafamidis pricing is not one number. Private-import pricing near SAR 820,000-850,000/year describes the pre-registration state; post-registration tender pricing near SAR 70,000-90,000 describes what follows.
NICE TA696 (May 2021, since updated by TA984) opened NHS commissioning of tafamidis for ATTR-CM at scale — acoramidis’s pending appraisal and vutrisiran’s TA868 access route are the two other decisions defining the UK amyloidosis market.
An estimated 500,000+ US patients aged 70+ have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated. A separate 100,000+ Val122Ile hereditary carrier pool sits alongside it.
ATTR-CM diagnostic abyss, Arabian Peninsula TTR variant registry, and the referral-pathway delay across GCC cardiology centres.
National Amyloidosis Centre-anchored epidemiology puts UK ATTRwt-CM prevalence at 20,000-40,000. Only 3,000-4,000 patients are on NICE-commissioned tafamidis today, leaving 15,000-36,000 undiagnosed.
AXLRx publishes Competitive Intelligence, Payer & HTA, Disease Landscape, Launch Readiness, Patient Flow Model, Market Sizing Model, KOL Mapping, HTA Strategy Model, and Pricing Strategy Model for Transthyretin Amyloidosis. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current ATTR Amyloidosis coverage spans United States, United Kingdom, and GCC (Gulf). Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest ATTR Amyloidosis reports were updated July 2026.